Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Sapropterin dihydrochloride 500 MG Powder for Oral Solution [Kuvan]

Known as: KUVAN 500 MG Powder for Oral Solution, Kuvan 500 MG (sapropterin 384 MG) Powder for Oral Solution, SAPROPTERIN DIHYDROCHLORIDE 500 mg ORAL POWDER, FOR SOLUTION [Kuvan] 
 
National Institutes of Health

Related topics

Related topics

8 relations
Ascorbic AcidKuvanMannitolPowder for Oral Solution
Expand

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
HPLC-Based Analysis of Impurities in Sapropterin Branded and Generic Tablets
This work was aimed at the definition of a chromatographic method able to separate and quantify impurities present in sapropterin… Expand
2019
2019
Response to sapropterin hydrochloride (Kuvan®) in children with phenylketonuria (PKU): a clinical trial
Abstract Background Phenylketonuria (PKU) is one of the most common types of inborn error of metabolism. The mainstay of therapy… Expand
  • figure 1
  • table 1
2019
2019
Sapropterin reduces coronary artery malformation in offspring of pregestational diabetes mice.
Endothelial nitric oxide synthase (eNOS) and oxidative stress are critical to embryonic coronary artery development. Maternal… Expand
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
2017
2017
Kuvan materiaalisuus on ratkeamaton ongelma
 
2016
2016
Increasing tetrahydrobiopterin in cardiomyocytes adversely affects cardiac redox state and mitochondrial function independently of changes in NO production.
Tetrahydrobiopterin (BH4) represents a potential strategy for the treatment of cardiac remodeling, fibrosis and/or diastolic… Expand
Review
2012
Review
2012
Evolving patient selection and clinical benefit criteria for sapropterin dihydrochloride (Kuvan®) treatment of PKU patients.
PURPOSE To understand current patient selection, dosing, and response criteria used for sapropterin dihydrochloride (sapropterin… Expand
2011
2011
Pharmacotherapy Options in the Management of Phenylketonuria
Phenylketonuria (PKU) is an autosomal recessive disorder related to a deficiency in the enzyme phenylalanine hydroxylase (PAH… Expand
2011
2011
Mechanism of Action , Metabolism , and Pharmacokinetic Profile Mechanism of action
Phenylketonuria (PKU) is an autosomal recessive disorder related to a deficiency in the enzyme phenylalanine hydroxylase (PAH… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
2011
2011
Safety of extended treatment with sapropterin dihydrochloride in patients with phenylketonuria: results of a phase 3b study.
BACKGROUND Phenylketonuria (PKU) results from impaired breakdown of phenylalanine (Phe) due to deficient phenylalanine… Expand
Review
2007
Review
2007
Sapropterin dihydrochloride (Kuvan/phenoptin), an orally active synthetic form of BH4 for the treatment of phenylketonuria.
  • J. Burnett
  • IDrugs : the investigational drugs journal
  • 2007
    • Corpus ID: 41258441
Phenylketonuria (PKU) and mild hyperphenylalaninemia (HPA) are genetic disorders characterized by a deficiency in phenylalanine… Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE